業績紹介
2023年 論文
- Saito T, Kanao K, Matsumoto K, Fukumoto K, Igarashi D, Takahashi T, Kaneko G, Shirotake S, Nishimoto K, Mizuno R, Ishida M, Hara S, Oya M, Oyama M. New risk stratification for adjuvant nivolumab for high-risk muscle-invasive urothelial carcinoma. BJUI Compass. 2023 Oct 27;5(2):281-288. doi: 10.1002/bco2.298. PMID: 38371203; PMCID: PMC10869665.
- Kamitani R, Matsumoto K, Yokota K, Hirai S, Komori T, Kamisawa K, Yamanaka T, Oya M. Maintenance avelumab therapy for urothelial carcinoma in a hemodialysis patient: a case report. Int Cancer Conf J. 2023 Nov 13;13(1):58-62. doi: 10.1007/s13691-023-00636-4. PMID: 38187180; PMCID: PMC10764676.
- Kato T, Nakano Y, Hongo F, Katano H, Miyagawa T, Ueda K, Azuma H, Nozawa M, Hinata N, Hori J, Otoshi T, Shimizu N, Aizawa M, Osada S, Matsui A, Oya M, Eto M, Tomita Y, Shinohara N, Uemura H. Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART). Int J Urol. 2023 Dec 18. doi: 10.1111/iju.15345. Epub ahead of print. PMID: 38110838.
- Yanagita M, Muto S, Nishiyama H, Ando Y, Hirata S, Doi K, Fujiwara Y, Hanafusa N, Hatta T, Hoshino J, Ichioka S, Inoue T, Ishikura K, Kato T, Kitamura H, Kobayashi Y, Koizumi Y, Kondoh C, Matsubara T, Matsubara K, Matsumoto K, Okuda Y, Okumura Y, Sakaida E, Shibagaki Y, Shimodaira H, Takano N, Uchida A, Yakushijin K, Yamamoto T, Yamamoto K, Yasuda Y, Oya M, Okada H, Nangaku M, Kashihara N. Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022. Clin Exp Nephrol. 2024 Feb;28(2):85-122. doi: 10.1007/s10157-023-02415-0. Epub 2023 Oct 25. Erratum in: Clin Exp Nephrol. 2023 Dec 9;: PMID: 37878114; PMCID: PMC10808569.
- Sogano J, Takahashi S, Tanaka N, Kubo H, Okita H, Oya M, Toda M. Surgical Treatment for Metastatic Brain Tumor in the Cerebellar Hemisphere from Small- cell Neuroendocrine Carcinoma of the Urinary Bladder: A Case Report and Review of the Literature. NMC Case Rep J. 2023 Sep 29;10:235-239. doi: 10.2176/jns- nmc.2023-0058. PMID: 37869379; PMCID: PMC10584780.
- Grimm MO, Oya M, Choueiri TK, Motzer RJ, Schmidinger M, Quinn DI, Gravis- Mescam G, Verzoni E, Van den Eertwegh AJM, di Pietro A, Mariani M, Wang J, Thomaidou D, Albiges L. Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial. Eur Urol. 2024 Jan;85(1):8-12. doi: 10.1016/j.eururo.2023.09.016. Epub 2023 Oct 16. PMID: 37852850.
- Saito T, Matsumoto K, Tanaka N, Fukumoto K, Yasumizu Y, Takeda T, Morita S, Kosaka T, Mizuno R, Asanuma H, Hara S, Oya M. Prognostic impact of tumor ureteral invasion on recurrence after radical cystectomy. Int Urol Nephrol. 2024 Jan;56(1):129-135. doi: 10.1007/s11255-023-03808-6. Epub 2023 Sep 20. PMID: 37731158.
- Oya M, Kaneko S, Imai T, Tsujino T, Sunaya T, Okayama Y. Retraction Note: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment. Cancer Chemother Pharmacol. 2023 Sep 16. doi: 10.1007/s00280-023-04587-8. Epub ahead of print. PMID: 37715787.
- Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Joung JY, Sugimoto M, Sartor O, Liu YZ, Poehlein C, Barker L, Del Rosario PM, Armstrong AJ. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Oct;24(10):1094-1108. doi: 10.1016/S1470-2045(23)00382-0. Epub 2023 Sep 12. PMID: 37714168.
- Fujiwara S, Kosaka T, Nishimoto Y, Kamisawa K, Watanabe K, Baba Y, Takeda T, Matsumoto K, Oya M. Prognostic significance of serum testosterone level in patients with castration-resistant prostate cancer treated with cabazitaxel. Prostate. 2024 Jan;84(1):25-31. doi: 10.1002/pros.24620. Epub 2023 Sep 3. PMID: 37661578.
- Komori T, Kosaka T, Tanaka T, Watanabe K, Yasumizu Y, Mikami S, Oya M. Locally recurrent prostate cancer with RB1/TP53 alterations successfully treated by salvage focal brachytherapy: a case report. Am J Clin Exp Urol. 2023 Aug 15;11(4):339-343. PMID: 37645609; PMCID: PMC10461036.
- Blas L, Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNiP-RCC Investigators. Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study. Int J Urol. 2023 Sep;30(9):788-796. doi: 10.1111/iju.15265. Epub 2023 Aug 1. PMID: 37528632.
- Komori T, Matsumoto K, Kosaka T, Takeda T, Kamitani R, Yasumizu Y, Tanaka N, Morita S, Mizuno R, Asanuma H, Oya M. ASO Visual Abstract: Long-Term Prognosis and Treatment Strategy of Persistent PSA After Radical Prostatectomy. Ann Surg Oncol. 2023 Oct;30(11):6945. doi: 10.1245/s10434-023-13916-3. PMID: 37523116.
- Komori T, Matsumoto K, Kosaka T, Takeda T, Kamitani R, Yasumizu Y, Tanaka N, Morita S, Mizuno R, Asanuma H, Oya M. Long-Term Prognosis and Treatment Strategy of Persistent PSA After Radical Prostatectomy. Ann Surg Oncol. 2023 Oct;30(11):6936-6942. doi: 10.1245/s10434-023-13780-1. Epub 2023 Jul 7. PMID: 37418130.
- Matsumoto K, Komori T, Oya M. ASO Author Reflections: Discussing the Optimal Treatment Strategy Against Persistent PSA After Radical Prostatectomy. Ann Surg Oncol. 2023 Oct;30(11):6943-6944. doi: 10.1245/s10434-023-13815-7. Epub 2023 Jul 5. PMID: 37405665.
- Takeda T, Narita K, Yasumizu Y, Tanaka N, Matsumoto K, Morita S, Kosaka T, Mizuno R, Asanuma H, Jinzaki M, Oya M. Factors affecting the selection of eligible candidates for focal therapy for prostate cancer. World J Urol. 2023 Jul;41(7):1821-1827. doi: 10.1007/s00345-023-04444-6. Epub 2023 Jun 16. PMID: 37326655.
- Osawa T, Oya M, Okanishi T, Kuwatsuru R, Kawano H, Tomita Y, Niida Y, Nonomura N, Hatano T, Fujii Y, Mizuguchi M, Shinohara N. Clinical Practice Guidelines for tuberous sclerosis complex-associated renal angiomyolipoma by the Japanese Urological Association: Summary of the update. Int J Urol. 2023 Oct;30(10):808-817. doi: 10.1111/iju.15213. Epub 2023 Jun 6. PMID: 37278492.
- Saito T, Matsumoto K, Kosaka T, Yasumizu Y, Tanaka N, Takeda T, Morita S, Mizuno R, Asanuma H, Oya M. Strategy for PSA progression in patients undergoing salvage radiation for biochemical recurrence after radical prostatectomy. Int J Clin Oncol. 2023 May;28(5):707-715. doi: 10.1007/s10147-023-02322-0. Epub 2023 Mar 17. PMID: 36929093.
- Izawa M, Tanaka N, Murakami T, Anno T, Teranishi Y, Takamatsu K, Mikami S, Kakimi K, Imamura T, Matsumoto K, Oya M. Single-Cell Phenotyping of CD73 Expression Reveals the Diversity of the Tumor Immune Microenvironment and Reflects the Prognosis of Bladder Cancer. Lab Invest. 2023 Apr;103(4):100040. doi: 10.1016/j.labinv.2022.100040. Epub 2023 Jan 10. PMID: 36870289.
- Yamamoto D, Hongo H, Kosaka T, Aoki N, Oya M, Sato T. The sialyl-Tn antigen synthase genes regulates migration-proliferation dichotomy in prostate cancer cells under hypoxia. Glycoconj J. 2023 Apr;40(2):199-212. doi: 10.1007/s10719-023-10104-z. Epub 2023 Feb 18. PMID: 36806956.
- Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNiP-RCC investigators. Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial. Cancer Immunol Immunother. 2023 Jun;72(6):1903-1915. doi: 10.1007/s00262-023-03367-w. Epub 2023 Feb 2. PMID: 36729213.
- Grünwald V, Powles T, Kopyltsov E, Kozlov V, Alonso-Gordoa T, Eto M, Hutson T, Motzer R, Winquist E, Maroto P, Keam B, Procopio G, Wong S, Melichar B, Rolland F, Oya M, Rodriguez-Lopez K, Saito K, McKenzie J, Porta C. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. Eur Urol Oncol. 2023 Aug;6(4):437-446. doi: 10.1016/j.euo.2023.01.010. Epub 2023 Jan 29. PMID: 36720658; PMCID: PMC10875602.
- Anno T, Tanaka N, Takamatsu K, Hakozaki K, Kufukihara R, Baba Y, Takeda T, Matsumoto K, Morita S, Kosaka T, Mikami S, Nishihara H, Mizuno R, Oya M. Prognostic role of the innate immune signature CD163 and "eat me" signal calreticulin in clear cell renal cell carcinoma. Cancer Immunol Immunother. 2023 Jun;72(6):1779-1788. doi: 10.1007/s00262-023-03369-8. Epub 2023 Jan 17. PMID: 36646952.
- Shigeta K, Hasegawa M, Hishiki T, Naito Y, Baba Y, Mikami S, Matsumoto K, Mizuno R, Miyajima A, Kikuchi E, Saya H, Kosaka T, Oya M. IDH2 stabilizes HIF-1α-induced metabolic reprogramming and promotes chemoresistance in urothelial cancer. EMBO J. 2023 Feb 15;42(4):e110620. doi: 10.15252/embj.2022110620. Epub 2023 Jan 13. PMID: 36637036; PMCID: PMC9929641.
- Nakaigawa N, Tomita Y, Tamada S, Tatsugami K, Osawa T, Oya M, Kanayama H, Miura Y, Sassa N, Nishimura K, Nozawa M, Masumori N, Miyoshi Y, Kuroda S, Kimura A. Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma. Int J Clin Oncol. 2023 Mar;28(3):416-426. doi: 10.1007/s10147-022-02283-w. Epub 2023 Jan 3. PMID: 36595123; PMCID: PMC9988754.
- Larkin J, Oya M, Martignoni M, Thistlethwaite F, Nathan P, Ornstein MC, Powles T, Beckermann KE, Balar AV, McDermott D, Gupta S, Philips GK, Gordon MS, Uemura H, Tomita Y, Wang J, Michelon E, di Pietro A, Choueiri TK. Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial. Oncologist. 2023 Apr 6;28(4):333-340. doi: 10.1093/oncolo/oyac243. PMID: 36576173; PMCID: PMC10078905.
- Kobayashi H, Kosaka T, Nakamura K, Kimura T, Nishihara H, Oya M. Genomic analysis of aggressive ductal adenocarcinoma of the prostate. Cancer Med. 2023 Apr;12(7):8445-8451. doi: 10.1002/cam4.5573. Epub 2022 Dec 26. PMID: 36573306; PMCID: PMC10134333.
- Takahashi R, Asanuma H, Mizuno R, Oya M. Current clinical perspective of urological oncology in the adolescent and young adult generation. Int J Clin Oncol. 2023 Jan;28(1):28-40. doi: 10.1007/s10147-022-02251-4. Epub 2022 Dec 17. PMID: 36527578.
- Hakozaki K, Takeda T, Yasumizu Y, Tanaka N, Matsumoto K, Morita S, Kosaka T, Mizuno R, Asanuma H, Oya M. Predictors of urinary function recovery after laparoscopic and robot-assisted radical prostatectomy. Int Braz J Urol. 2023 Jan-Feb;49(1):50-60. doi: 10.1590/S1677-5538.IBJU.2022.0362. PMID: 36512455; PMCID: PMC9881801.
- Eto M, Takagi T, Kimura G, Fukasawa S, Tamada S, Miura Y, Oya M, Sassa N, Anai S, Nozawa M, Sakai H, Perini R, Yusa W, Ikezawa H, Narita T, Tomita Y. Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study. Cancer Med. 2023 Mar;12(6):6902-6912. doi: 10.1002/cam4.5483. Epub 2022 Dec 1. PMID: 36457273; PMCID: PMC10067092.
- Arai M, Kosaka T, Yasumizu Y, Takeda T, Matsumoto K, Oya M. Androgen deprivation therapy duration is significantly associated with Testosterone recovery in Japanese patients with prostate cancer. Int J Urol. 2023 Feb;30(2):235-239. doi: 10.1111/iju.15098. Epub 2022 Nov 14. PMID: 36375076.
- Uemura H, Oya M, Kamoto T, Sugimoto M, Shinozaki K, Morita K, Koto R, Takahashi M, Nii M, Shin E, Nonomura N. The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi- institutional observational ZENSHIN study. Cancer Med. 2023 Mar;12(5):5265-5274. doi: 10.1002/cam4.5333. Epub 2022 Nov 10. PMID: 36358026; PMCID: PMC10028105.
- Tomita Y, Kobayashi K, Kimura G, Oya M, Uemura H, Nishiyama H, Galsky MD, Nasroulah F, Collette S, Broughton E, Ünsal-Kaçmaz K, Kamisuki Y, Bajorin DF. Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial. Jpn J Clin Oncol. 2023 Jan 6;53(1):16-25. doi: 10.1093/jjco/hyac155. PMID: 36300304; PMCID: PMC9825712.
- Kamitani R, Matsumoto K, Takeda T, Mizuno R, Oya M. Evaluation of prognostic factors and treatment options for renal angiosarcoma: A retrospective analysis of 113 reported cases. Eur J Surg Oncol. 2023 Jan;49(1):263-270. doi: 10.1016/j.ejso.2022.09.001. Epub 2022 Sep 8. PMID: 36116986.
- Umeda K, Tanaka N, Yasumizu Y, Takeda T, Matsumoto K, Morita S, Kosaka T, Mizuno R, Oya M. Site-Specific Differences in PD-1 Blockade Success and Biomarkers in Urothelial Carcinoma Treated with Pembrolizumab. Clin Genitourin Cancer. 2023 Feb;21(1):128-135. doi: 10.1016/j.clgc.2022.08.004. Epub 2022 Aug 7. PMID: 36058808.
- Hongo H, Kosaka T, Suzuki Y, Oya M. Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening. Prostate Cancer Prostatic Dis. 2023 Mar;26(1):59-66. doi: 10.1038/s41391-021-00426-0. Epub 2021 Sep 30. PMID: 34593983; PMCID: PMC10023558.
